Navigation Links
Accelerating Drug Development Through Drug & Companion Diagnostic Co-development, New Life Science Webinar Hosted by Xtalks
Date:10/2/2013

Toronto, Canada (PRWEB) October 02, 2013

The past decade has seen a transition from the traditional model of drug development to a more targeted, personalized approach to drug development and clinical trial design. The use of a companion diagnostic strategy is increasingly an essential component of the drug development process where it facilitates optimal patient stratification and outcome management. Parallel development of the drug and its companion diagnostic assay affords simplified logistics, economies of scale and the potential to accelerate the drug development process through optimal patient selection. The application of the companion diagnostic within the corresponding drug trial also provides valuable insight into the use of the companion diagnostic in a clinical setting and produces valuable data to support the regulatory filing of both the drug and the companion diagnostic.

Dr. Mark Roberts, Director of Diagnostic Development at Covance, will discuss the emerging field of companion diagnostics with focus on its importance in clinical trial design and how drug / companion diagnostic co-development is rapidly changing the drug development process.

A Q&A with the audience will follow the main presentation.

For more information about this event or to register, visit: http://xtalks.com/Drug-and-Companion-Diagnostic-Co-Development.ashx

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx.

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/10/prweb11172002.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. McGladrey Manufacturing and Distribution Monitor® Shows Business Accelerating Despite Concerns About Government Gridlock
2. Patheon to Host Webinar on “Accelerating the Drug Development Trajectory by Improving Solubility of New Compounds”
3. Accelerating Drug Development by Harnessing Technology: New Life Science webinar Hosted by Xtalks
4. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
5. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
6. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
7. Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
8. ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents
9. Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
10. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
11. Idenix Reports Advancement of HCV Development Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... and GREENWICH, Conn. , Feb. ... firm focused on venture growth investments in biotechnology ... Josh Richardson , M.D. to Managing Director. ... biotechnology companies.  He is a board observer at ... in Longitude,s investments in Aimmune Therapeutics, Akebia Therapeutics, ...
(Date:2/16/2017)... CALABASAS, Calif. , Feb. 16, 2017 /PRNewswire/ ... on developing groundbreaking therapies to treat severe neurological ... in children treated with AGT-181, the company,s investigational ... syndrome (also known as mucopolysaccharidosis type I, or ... Phase 2 proof-of-concept (POC) study, presented today at ...
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , February 16, 2017 ... infusion of innovative telemedicine application, new and leading ... are experiencing a boom worldwide. The healthcare sector ... of technologies, services and new therapies for companies ... (TSX-V: RHT), Cellectar Biosciences, Inc. (NASDAQ: ...
Breaking Biology Technology:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a community ... that it has received Laboratory Accreditation from the ... is presented to laboratories that meet stringent requirements ... scientifically rigorous processes. "Genos is committed ... laboratory practices. We,re honored to be receiving CAP ...
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist ... as its new chief executive officer (CEO). Freischlag joins ... John D. McConnell , M.D., who last year ... at the Medical Center, after leading it since 2008. ... full scope of Wake Forest Baptist,s academic health system, ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
Breaking Biology News(10 mins):